PubMed Health⌕ Search

Biomedical subjects

J Labenz

Publications and source records attributed to J Labenz.

At least 109 records · Page 6Linked to original sources
PubMed1994

[Helicobacter pylori therapy with omeprazole and clarithromycin: current status].

Clarithromycin and its 14-OH-metabolite are highly effective against Helicobacter pylori in vitro. This drug is acid stable and soluble and reaches considerable concentrations in the gastric mucosa and the mucus layer after oral administration. Several studies have meanwhile demonstrated that combined treatment with omeprazole and clarithromycin may eradicate. H. pylori infection in a remarkable proportion of treated patients. On the basis of the results of a recently published randomized doubleblind multicenter trial, at two-week therapy course comprising omeprazole 40 mg once in the morning and clarithromycin 500 mg thrice daily can be recommended for routine practice. One-week low dose triple therapy regimens combining omeprazole, clarithromycin and tinidazole or metronidazole might be a valuable alternative to omeprazole enhanced antibiotic monotherapy in the future, but the encouraging results of three pilot studies (H. pylori cure rates: 90%-100%) have to be confirmed in randomized and controlled trials.

Clarithromycin↗
PubMed1994

[24-hour gastric pH profile with 2 x 20 mg and 2 x 40 mg omeprazole in patients with Helicobacter pylori-associated gastroduodenal ulcer disease].

Fifty patients suffering from Helicobacter pylori associated duodenal (n = 25) or gastric ulcer disease (n = 25) were randomly treated with either omeprazole 20 mg b.i.d. (n = 25) or 40 mg b.i.d. (n = 25). From day 8 to 9, a 24-hour gastric pH measurement was performed in all patients. Patients with duodenal ulcer disease treated with 40 mg or 80 mg omeprazole demonstrated similar gastric pH patterns without statistically significant differences with regard to the mean (5.10 versus 5.17, p = 0.6439) and median pH (5.35 versus 5.30, p = 0.8277) as well as to the percent of time spent below distinctive pH thresholds. Patients suffering from gastric ulcer disease respond somewhat better to the higher omeprazole dose as compared to the 40 mg omeprazole regimen reaching statistical significance (mean pH: 5.04 versus 5.74, p = 0.0124; median pH: 5.30 versus 5.95, p = 0.0114; %-time spent below pH 2, 3, 4, and 5, respectively). In conclusion, there was virtually no (duodenal ulcer) or only a slight (gastric ulcer), probably clinically irrelevant, benefit to doubling the omeprazole dose (20 mg b.i.d. vs. 40 mg b.i.d.) with regard to the 24-hour gastric pH patterns.

Adult↗
PubMed1994

Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease.

OBJECTIVE: To compare the efficacy of two omeprazole/amoxicillin regimens concerning Helicobacter pylori eradication, ulcer healing, pain relief, and safety in patients with gastric ulcer disease. METHODS: In a prospective, single-blind, single-center study, 70 patients with active, H. pylori-positive (histology and/or culture) gastric ulcers were randomly treated with either omeprazole 20 mg b.i.d. plus amoxicillin 1 g b.i.d. (group I; n = 35) or with omeprazole 40 mg b.i.d. plus amoxicillin 1 g b.i.d. over 2 wk, followed by full dose ranitidine for another 4 wk. Patients were investigated clinically and endoscopically prior to treatment and after 6 wk, including the assessment of H. pylori status by means of urease test, specific culture, and histology. RESULTS: Patients of group I and II had similar demographic and clinical characteristics. Three patients were lost to follow-up. The overall proportion of H. pylori eradication was 88.1% (group I, 91.2%; group II, 84.8%, p = NS). The ulcer healing rate was 79.1% after 6 wk, 92.5% after 10 wk, and 100% after 6 months, without a statistically significant difference between the study groups. Complete pain relief occurred after a median of 2 days (group I) and 1.5 days (group II, p = NS), respectively. Six patients (9.0%) complained of side effects that led to discontinuation of amoxicillin treatment in three patients (4.5%). CONCLUSIONS: Omeprazole plus amoxicillin is a highly effective and well-tolerated therapy regimen to eradicate H. pylori from the gastric mucosa of patients with gastric ulcer disease. In addition, the results clearly suggest that medium- and high-dose omeprazole schedules are equally effective with regard to bacterial eradication, ulcer healing, pain relief, and safety in gastric ulcers. Thus, medium- and not high-dose omeprazole plus amoxicillin should be the treatment regimen of first choice to eradicate H. pylori in gastric ulcer disease.

Adult↗
PubMed1994

[Omeprazole modified antibiotic therapy of Helicobacter pylori infection: can clarithromycin be replaced by roxithromycin?].

Thirty-five consecutive patients (median age: 50 years, 17 men and 18 women) suffering from Helicobacter pylori associated peptic ulcer disease (duodenal ulcer: n = 15, gastric ulcer: n = 13) or severe functional dyspepsia (n = 7) were enrolled in a two-center clinical trial and treated with omeprazole 20 mg bid preprandially and roxithromycin 300 mg bid postprandially over two weeks. After cessation of the study medication, ulcer patients received a full dose H2-blocker treatment up to the final examination four weeks later. All patients completed the trial without contravening the protocol. Side effects were not recorded. The overall proportion of cure of Helicobacter pylori-infection was 29% (10 out of 35 patients) without statistically significant difference between the two participating centers (center I: 7 out of 20 patients [35%], center II: 3 out of 15 patients [20%]; p = 0.33). We conclude from our results that omeprazole plus roxithromycin is an ineffective treatment schedule with regard to cure of H.pylori-infection in patients with peptic ulcer disease or dyspepsia.

Adult↗
PubMed1994

Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy.

OBJECTIVES: The aim of the present study was to examine the effect of the application route of the antibiotic amoxicillin in Helicobacter pylori eradication, using omeprazole/amoxicillin. METHODS: In a prospective medium-term study, 31 patients with H. pylori-positive gastroduodenal ulcer disease were treated with a 14-day course of 20 mg omeprazole bid orally, combined with either 1 g amoxicillin tid intravenously (n = 15) or 500 mg amoxicillin six times daily orally (n = 16). RESULTS: H. pylori eradication, defined as negative bacterial findings in urease test, culture, and histology at least 4 wk after cessation of study medication, was achieved in 93% (14/15) of the patients in the first group and in 91% (11/12) of the patients in the second group. To obtain medium-term results, patients in whom H. pylori had been successfully eradicated were investigated with a 13C-urea breath test at least 6 months later. Medium-term eradication rates of 91% (10/11 patients) in the first and 100% (10/10 patients) in the second group were observed. CONCLUSIONS: In view of the equally high eradication rates obtained by a 14-day course of intravenously administered amoxicillin and an oral therapy of the same length and dosage, during the necessary induction of luminal hypoacidity by the proton pump inhibitor omeprazole, we conclude that the route of administration of amoxicillin does not play a decisive role in bacterial eradication.

Administration, Oral↗
PubMed1993

[Oral triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease].

25 patients with Helicobacter pylori-associated active duodenal ulcer disease (bleeding: n = 5, penetrating: n = 1, stenosis of the bulb: n = 4, frequent ulcer relapse: n = 18) were treated with 3 x 600 mg bismuth subsalicylate (BSS), 3 x 400 mg metronidazole and 3 x 500 mg tetracycline in addition to 300 mg ranitidine. 23 out of 25 patients (92%) proved to be Helicobacter pylori-negative four weeks after cessation of study medication as judged from negative urease test, specific culture and histology after modified Giemsa staining. 24/25 ulcers (96%) had healed after six weeks. In one patient on NSAIDs a small duodenal ulcer was detected on the final endoscopic examination despite successful Helicobacter pylori eradication. Twelve out of 25 (48%) patients complained side effects that did not lead to discontinuation of therapy. In conclusion, oral triple therapy with BSS, metronidazole and tetracycline is highly effective in Helicobacter pylori eradication, but there was a rather high rate of more or less serious side effects, diminishing the attractiveness of this therapeutic regimen.

Administration, Oral↗
PubMed1993

[Is Helicobacter pylori gastritis a macroscopic diagnosis?].

In a prospective study, gastroscopy and biopsies from the gastric antrum and body were undertaken in 100 consecutive patients (67 women, 33 men; mean age 58.6 [11-90] years) with unknown Helicobacter pylori status. None had been on any bacteria-suppressing drugs. Main indications for gastroscopy were upper abdominal pain, dyspepsia, emesis and anaemia of unknown cause. The macroscopic criteria for the diagnosis of H. pylori gastritis were the presence of at least one of the following signs: (1) chronic antral erosions; (2) goose-pimple-like appearance of the antral mucosa; (3) spotty erythema in the antrum; (4) complex changes of the antral mucosa with both bizarre reddening and pale areas; and (5) increased areolar markings and diffuse or fine-spotty erythema in the mucosa of the body of the stomach. Four biopsies each from the antrum and body were examined with the urease quick-test, microscopically as smears, specific culture and histology as reference methods. 60 patients had H. pylori gastritis, recognized macroscopically in 59 (sensitivity 98.3%). A false-positive diagnosis was made in 10 of 40 H. pylori-negative patients (specificity 75%). The positive predictive value of macroscopic diagnosis was 85.5%, the negative predictive value 96.8%.

Adolescent↗
PubMed1993

Bleeding watermelon stomach treated by Nd-YAG laser photocoagulation.

We report on five patients with liver disease requiring blood transfusion because of recurrent acute or chronic bleeding from diffuse antral vascular ectasia (watermelon stomach). All were initially misinterpreted as hemorrhagic gastritis. Medical treatment with antiulcer drugs failed to control blood loss. Nd-YAG laser therapy (medium number of sessions: n = 4, range: 1-8) improved the endoscopic appearance of the gastric lesions and effectively controlled blood loss in all patients over a medium follow up period of eight months (range: 2-12 months). Treatment related complications did not occur.

Adult↗
PubMed1993

Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study.

Treatment with amoxicillin and omeprazole resulted in encouraging Helicobacter pylori eradication rates in pilot studies that included medium term follow up. These results were evaluated in a prospective, randomised and controlled study. Forty patients with active duodenal ulcer disease and H pylori colonisation of the gastric mucosa were randomly assigned to receive either omeprazole (20 mg twice daily) and amoxicillin suspension (500 mg four times daily) for two weeks (group I) or bismuth subsalicylate (600 mg three times daily), metronidazole (400 mg three times daily), tetracycline (500 mg three times daily), and ranitidine (300 mg in the evening) for two weeks (group II). Study medication was followed in both groups by a four week treatment course with 300 mg ranitidine up to the final examination. One patient from each group was lost to follow up. H pylori was eradicated in 78.9% of group I and 84.2% of group II (p = 1.00). All ulcers in patients on omeprazole plus amoxicillin healed but in the triple treatment group four patients had residual peptic lesions after six weeks (ulcer healing rate: 78.9%, p = 0.11). Complete pain relief occurred after a median duration of 1 day in group I and of 6 days in group II (p = 0.03). There were no major complications in either group but minor side effects were more frequently recorded in patients on triple therapy (63.2% v 15.8%, p < 0.01). In conclusion, two weeks of treatment with omeprazole plus amoxicillin is as good as triple therapy plus ranitidine in eradicating H pylori but seems better with regard to safety, pain relief, and ulcer healing. Thus, amoxicillin plus omeprazole should be recommended as the treatment of choice in eradicating H pylori in patients with duodenal ulcer disease.

Adult↗
PubMed1993

Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori.

In five subsequent open clinical studies, 180 patients with Helicobacter pylori (HP)-associated ulcer disease (n = 163) or severe functional dyspepsia (n = 17) requiring therapy were treated with either 40 mg omeprazole plus 4 x 500 mg amoxicillin suspension for 1 wk (group I, n = 35), 2 x 40 mg omeprazole plus 4 x 500 mg amoxicillin for 1 wk (group II, n = 50), 2 x 20 mg omeprazole plus 4 x 500 mg amoxicillin for 2 wk (group III, n = 62), 2 x 20 mg omeprazole (day 1-14) and 4 x 500 mg amoxicillin (day 8-14) (group IV, n = 22) or with 2 x 20 mg omeprazole for 2 wk (group V, n = 11). The HP eradication rates determined with a biopsy urease test, microscopy of a mucosal smear, specific culture, and histology after modified GIEMSA staining in the 5th wk after discontinuation of study medication were 61.3% in group I, 61.7% in group II, 82.8% in group III, 28.6% in group IV, and 0% in group V. Apart from clinical insignificant pharyngeal paresthesias (n = 6), nine patients (5.7%) with combined therapy complained of important side effects (stomatitis: n = 3, diarrhea: n = 3, allergic exanthema: n = 3) that led to termination of amoxicillin treatment in four cases (2.5%). We conclude that omeprazole-enhanced amoxicillin antibiosis is a simple and effective approach to the eradication of HP colonization.

Adult↗
PubMed1992

[Bleeding gastric and duodenal varicose veins: endoscopic embolisation using tissue adhesives].

Endoscopically guided intravascular injections of the tissue glue N-butyl-2-cyanoacrylate have since 1990 been performed in eight patients (seven men, one woman; median age 59.5 [40-72] years) with cirrhosis of the liver (alcoholic: n = 6, posthepatic, n = 2), decreased haemoglobin (6-10 g/dl) and transient shock symptoms (n = 5) due to gastric (n = 7) or duodenal varices (n = 1). Gastric acid production was suppressed with omeprazole. Neither balloon catheters nor drugs were used to lower portal vein pressure. Initial haemostasis was achieved in all patients. One patient with consumption coagulopathy died of recurrent bleeding from varices in the body of the stomach which could be only temporarily arrested. Another patient had a recurrence of bleeding from varices in the cardia 3 months after the initial treatment: it was again controlled by endoscopic sclerotherapy with tissue glue. All other patients remain free of bleeding after a mean observation time of 8.4 months.

Adult↗
PubMed1992

[Short-term therapy with high dosage omeprazole and amoxicillin for Helicobacter pylori eradication. A pilot study].

In an open study, 50 patients with Helicobacter pylori-associated ulcer disease or severe functional dyspepsia were treated over one week with 2 x 40 mg omeprazole in the morning and evening preprandially and 4 x 500 mg amoxicillin suspension one hour before meals and at night. Fourty-seven patients (ulcer disease: n = 40, functional dyspepsia: n = 7) completed the study without contravening the protocol. The proportion of Helicobacter pylori eradication four weeks after cessation of study medication was 61.7% (29/47 patients) as judged from negative biopsy urease test, specific culture and histology after modified Giemsa staining. Three patients experienced side effects (stomatitis, self-limiting diarrhea, allergic exanthema).

Amoxicillin↗